A new UC Davis MIND Institute study offers critical insights into Rett syndrome, a rare genetic condition that affects mostly girls. The research reveals how this condition affects males and females ...

An American journalist is sharing that his 6-year-old son died following a years-long battle with a rare, incurable disorder called Rett syndrome. On Aug. 18, NBC News chief foreign correspondent ...

Gene therapy may offer hope for people with a rare childhood disease called Rett syndrome. Around one in 10,000 girls are born each year with Rett syndrome, a rare genetic condition that impacts brain ...

Please provide your email address to receive an email when new articles are posted on . A new machine learning model that incorporates cardiac activity and body movement may help estimate the severity ...

Richard Engel, chief foreign correspondent for NBC News, announced on Thursday that his 6-year-old son Henry, diagnosed with Rett syndrome as an infant, had died. In a tweet posted on Aug. 18, Engel ...

Rett syndrome is a rare neurodegenerative disorder that almost exclusively affects girls. It is typically diagnosed in babies between six and 18 months of age, when the first symptoms begin to appear.

Patient advocate Paige Nues elaborates on the patient journey associated with a Rett syndrome diagnosis. Paige Nues: Often, a pediatrician may not be familiar with something as complex as Rett ...

Credit: Getty Images. Trofinetide is a novel synthetic analogue of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome. The Food and Drug Administration (FDA) ...

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc.

Credit: Acadia Pharmaceuticals. The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study. The Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has approved trofinetide oral solution (Daybue, Acadia Pharmaceuticals) as the first treatment of Rett syndrome in adults and children aged 2 years and older.

Paige Nues, from the International Rett Syndrome Foundation, provides insights on the diagnostic journey for patients with Rett syndrome. Paige Nues: The diagnostic journey for someone with Rett ...